Ro Telehealth in 2026: Major Glp-1 Program Updates, Pricing Shifts, and Review Breakdown
By Maya Lin-Takahashi
Ro is not operating in a vacuum. Its closest direct competitor, Hims & Hers Health, pursues an overlapping customer base with a notably different strategic emphasis. Comparing Ro vs Hers highlights diverging approaches to patient onboarding and pharmaceutical sourcing.
Hers leans heavily into cash-pay models, frequently steering customers directly toward bundled compounded treatments or customized oral formulations containing bupropion, naltrexone, and metformin. This approach bypasses commercial insurance entirely, providing customers with a predictable all-in price tag, often between $199 and $299 per month, without surprise prior authorization delays.
Ro places greater emphasis on securing commercial insurance coverage for FDA-approved brand-name therapies before defaulting to compounded medications. This strategy benefits patients with comprehensive employer insurance policies that cover anti-obesity drugs, allowing them to receive branded treatments at low copays. Conversely, it frustrates patients who spend weeks stuck in prior authorization limbo while Ro’s recurring software membership continues billing their accounts.
In the hair restoration space, both platforms offer virtually identical medical options: finasteride, dutasteride, topical minoxidil, and combination foam solutions. Ro stands out by offering more robust blood-testing tie-ins and broader specialty care, whereas Hers focuses on streamlined onboarding and lower subscription price floors.
Maya is a hardware enthusiast who tests and reviews smart home devices, smartphones, wearables, and audio gear. She focuses on practical consumer value and build quality.
